Robbins Farley’s AbbVie ABBV Stock Holding History

Robbins Farley’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-18	Closed	-$4.17K	–	147
2025 Q3	$4.17K	Buy	+18	New	+$3.67K	﹤0.01%	126
2024 Q1	–	Sell	-150	Closed	-$23.2K	–	168
2023 Q4	$23.2K	Sell	150 -668	-82%	-$97.4K	0.01%	92
2023 Q3	$122K	Buy	818 +150	+22%	+$22K	0.08%	64
2023 Q2	$90K	Sell	668 -171	-20%	-$25.1K	0.06%	66
2023 Q1	$134K	Buy	839 +150	+22%	+$22.9K	0.09%	61
2022 Q4	$111K	Buy	689 +21	+3%	+$3.22K	0.09%	58
2022 Q3	$90K	Sell	668 -50	-7%	-$7.17K	0.07%	67
2022 Q2	$110K	Sell	718 -280	-28%	-$42.8K	0.11%	47
2022 Q1	$162K	Buy	998 +50	+5%	+$7.26K	0.12%	54
2021 Q4	$128K	Hold	948	–	–	0.09%	52
2021 Q3	$102K	Buy	+948	New	+$108K	0.08%	59
2021 Q2	–	Sell	-948	Closed	-$110K	–	93
2021 Q1	$110K	Buy	+948	New	+$101K	0.1%	58

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Robbins Farley's ABBV Position: Q4 2025 in Review

Robbins Farley sold out of AbbVie (ABBV) in Q4 2025, closing a stake of 18 shares — an estimated $4.17K sold.

Robbins Farley first reported a position in ABBV in Q1 2021 and held it in 12 quarters. The position peaked at $162K in Q1 2022. 4,156 funds tracked by Wall St. Rank hold ABBV as of Q4 2025.

Robbins Farley reported no remaining AbbVie position as of Q4 2025 after selling out during the quarter.
Robbins Farley sold 18 AbbVie shares in Q4 2025, an estimated $4.17K.
Robbins Farley first reported a position in AbbVie in Q1 2021 and held it in 12 quarters.
Robbins Farley's AbbVie position peaked at $162K in Q1 2022.
4,156 funds tracked by Wall St. Rank held AbbVie as of Q4 2025.

Based on Robbins Farley's 13F filing for Q4 2025, filed 23 Jan 2026.